Darvon w/ asa, Peyona (previously nymusa)(caffeine, citrated)
Anoquan, Cafcit, Cafergot, Darvon, Dhc, Esgic, Excedrin (migraine Relief), Femcet, Fioricet, Fiorinal, Gencebok, Invagesic, Lanorinal, Medigesic, Norgesic, Nymusa, Peyona, Synalgos-dc, Synalgos-dc-a, Triad, Wigraine (caffeine, citrated) is a small molecule pharmaceutical. Caffeine, citrated was first approved as Darvon w/ asa on 1982-01-01. It has been approved in Europe to treat apnea.
Download report
Favorite
Commercial
Trade Name
FDA
EMA
Cafcit (generic drugs available since 1983-10-04)
CombinationsExcedrin (migraine relief), Fioricet (generic drugs available since 1983-10-04, discontinued: , Anoquan, Cafergot, Darvon, Darvon w/ asa, Dhc, Esgic, Femcet, Fiorinal, Invagesic, Lanorinal, Medigesic, Norgesic, Synalgos-dc, Synalgos-dc-a, Triad, Wigraine)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Acetaminophen
+
Aspirin
+
Caffeine
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| EXCEDRIN (MIGRAINE RELIEF) | GSK | N-020802 OTC | 1998-01-14 | 1 products, RLD, RS |
Acetaminophen
+
Butalbital
+
Caffeine
+
Codeine phosphate
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| FIORICET W/ CODEINE | Allergan | N-020232 RX | 1992-07-30 | 1 products, RLD, RS |
Aspirin
+
Butalbital
+
Caffeine
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| FIORINAL | Allergan | N-017534 DISCN | 1986-04-16 | 2 products, RLD |
Hide discontinued
Aspirin
+
Butalbital
+
Caffeine
+
Codeine phosphate
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| FIORINAL W/CODEINE | Allergan | N-019429 DISCN | 1990-10-26 | 1 products, RLD |
Hide discontinued
Aspirin
+
Caffeine
+
Dihydrocodeine bitartrate
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| SYNALGOS-DC | Sun Pharmaceutical Industries | N-011483 DISCN | 1983-09-06 | 1 products, RLD |
Hide discontinued
Aspirin
+
Caffeine
+
Orphenadrine citrate
Aspirin
+
Caffeine
+
Propoxyphene hydrochloride
Aspirin
+
Propoxyphene hydrochloride
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| DARVON W/ ASA | Xanodyne Pharmaceuticals | N-010996 DISCN | 1982-01-01 | 1 products |
Hide discontinued
Caffeine
+
Ergotamine tartrate
Caffeine citrate
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| CAFCIT | Hikma Pharmaceuticals | N-020793 RX | 1999-09-21 | 1 products, RLD, RS |
Show 1 discontinued
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| cafergot | ANDA | 2019-12-16 |
| darvon-n | New Drug Application | 2009-10-27 |
| esgic | ANDA | 2022-11-09 |
| extra strength pain relief | OTC monograph not final | 2023-06-21 |
| fioricet | ANDA | 2021-01-01 |
| migergot | ANDA | 2019-08-14 |
| norgesic | ANDA | 2022-05-17 |
| orphengesic forte | ANDA | 2021-04-28 |
| trezix | ANDA | 2022-05-02 |
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
No data
HCPCS
No data
Clinical
Clinical Trials
356 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Healthy volunteers/patients | — | 24 | 1 | — | 3 | 23 | 51 | ||
| Apnea | D001049 | HP_0002104 | R06.81 | 1 | 1 | 4 | 3 | 7 | 16 |
| Migraine disorders | D008881 | EFO_0003821 | G43 | — | 2 | 3 | 2 | 1 | 7 |
| Pain | D010146 | EFO_0003843 | R52 | — | 1 | 3 | 2 | 1 | 7 |
| Type 2 diabetes mellitus | D003924 | EFO_0001360 | E11 | 3 | — | — | 1 | 2 | 6 |
| Neoplasms | D009369 | C80 | 4 | 1 | — | 1 | — | 6 | |
| Affect | D000339 | — | — | — | 1 | 5 | 6 | ||
| Reperfusion injury | D015427 | — | — | — | 2 | 2 | 4 | ||
| Bronchopulmonary dysplasia | D001997 | P27.8 | — | — | 1 | 1 | 1 | 3 | |
| Cardiovascular diseases | D002318 | EFO_0000319 | I98 | — | — | — | 2 | 1 | 3 |
Show 20 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Obesity | D009765 | EFO_0001073 | E66.9 | 3 | 1 | 1 | — | 6 | 11 |
| Postoperative pain | D010149 | G89.18 | 1 | 1 | 1 | — | 1 | 4 | |
| Parkinson disease | D010300 | EFO_0002508 | G20 | 1 | 2 | 2 | — | — | 4 |
| Atrial fibrillation | D001281 | EFO_0000275 | I48.0 | — | — | 1 | — | 2 | 3 |
| Hypoxia | D000860 | R09.02 | — | 1 | 1 | — | 1 | 3 | |
| Alzheimer disease | D000544 | EFO_0000249 | F03 | 2 | — | 1 | — | — | 3 |
| Coronary artery disease | D003324 | I25.1 | — | — | 1 | — | 2 | 3 | |
| Headache | D006261 | HP_0002315 | R51 | — | — | 1 | — | 1 | 2 |
| Arthralgia | D018771 | HP_0002829 | M25.5 | — | — | 1 | — | 1 | 2 |
| Premature birth | D047928 | EFO_0003917 | O60 | — | — | 1 | — | — | 1 |
Show 16 more
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Breast neoplasms | D001943 | EFO_0003869 | C50 | 1 | 1 | — | — | — | 2 |
| Dyspnea | D004417 | HP_0002094 | R06.0 | — | 1 | — | — | 1 | 2 |
| Postoperative complications | D011183 | — | 1 | — | — | 1 | 2 | ||
| Spinal cord injuries | D013119 | EFO_1001919 | 1 | 1 | — | — | 1 | 2 | |
| Obstructive sleep apnea | D020181 | EFO_0003918 | G47.33 | — | 1 | — | — | 1 | 2 |
| Stroke | D020521 | EFO_0000712 | I63.9 | — | 1 | — | — | 1 | 2 |
| Narcolepsy | D009290 | EFO_0000614 | G47.4 | 1 | 1 | — | — | — | 1 |
| Retinopathy of prematurity | D012178 | EFO_1001158 | H35.1 | — | 1 | — | — | — | 1 |
| Amblyopia | D000550 | H53.00 | 1 | 1 | — | — | — | 1 | |
| Perceptual disorders | D010468 | R41.4 | — | 1 | — | — | — | 1 |
Show 8 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Drug interactions | D004347 | 3 | — | — | — | 1 | 4 | ||
| Rheumatoid arthritis | D001172 | EFO_0000685 | M06.9 | 3 | — | — | — | 1 | 4 |
| Pharmacokinetics | D010599 | 2 | — | — | — | 1 | 3 | ||
| Brain hypoxia-ischemia | D020925 | EFO_1000846 | P91.6 | 2 | — | — | — | — | 2 |
| Psoriasis | D011565 | EFO_0000676 | L40 | 2 | — | — | — | — | 2 |
| Atopic dermatitis | D003876 | EFO_0000274 | L20 | 2 | — | — | — | — | 2 |
| Melanoma | D008545 | 1 | — | — | — | — | 1 | ||
| Liver diseases | D008107 | EFO_0001421 | K70-K77 | 1 | — | — | — | — | 1 |
| Pure autonomic failure | D054970 | 1 | — | — | — | — | 1 | ||
| Orthostatic hypotension | D007024 | I95.1 | 1 | — | — | — | — | 1 |
Show 18 more
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Placebos | D010919 | — | — | — | — | 6 | 6 | ||
| Sleep deprivation | D012892 | F51.12 | — | — | — | — | 4 | 4 | |
| Overactive urinary bladder | D053201 | EFO_1000781 | N32.81 | — | — | — | — | 4 | 4 |
| Fatigue | D005221 | HP_0012378 | R53.83 | — | — | — | — | 3 | 3 |
| Pediatric obesity | D063766 | — | — | — | — | 3 | 3 | ||
| Mental fatigue | D005222 | — | — | — | — | 3 | 3 | ||
| Analgesia | D000698 | — | — | — | — | 2 | 2 | ||
| Sleep initiation and maintenance disorders | D007319 | F51.01 | — | — | — | — | 2 | 2 | |
| Anxiety | D001007 | EFO_0005230 | F41.1 | — | — | — | — | 2 | 2 |
| Feeding behavior | D005247 | — | — | — | — | 2 | 2 |
Show 81 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | CAFFEINE, CITRATED |
| INN | — |
| Description | Caffeine citrate, sold under the brand name Cafcit among others, is a medication used to treat a lack of breathing in premature babies. Specifically it is given to babies who are born at less than 35 weeks or weigh less than 2 kilograms (4.4 lb) once other causes are ruled out. It is given by mouth or slow injection into a vein.
|
| Classification | Small molecule |
| Drug class | — |
| Image (chem structure or protein) | |
| Structure (InChI/SMILES or Protein Sequence) | Cn1c(=O)c2c(ncn2C)n(C)c1=O.O=C(O)CC(O)(CC(=O)O)C(=O)O |
Identifiers
| PDB | — |
| CAS-ID | 2097117-68-3 |
| RxCUI | — |
| ChEMBL ID | CHEMBL1200569 |
| ChEBI ID | — |
| PubChem CID | 6241 |
| DrugBank | — |
| UNII ID | — |
Target
Agency Approved
No data
Alternate
No data
Variants
Clinical Variant
No data
Financial
Migergot - Horizon Therapeutics Public
$
€
£
₣
Mock data
Subscribe for the real data
Subscribe for the real data
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 89,484 documents
View more details
Safety
Black-box Warning
Black-box warning for: Cafergot, Darvon-n, Fioricet, Migergot, Trezix
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
19,121 adverse events reported
View more details
Premium feature
Learn more about premium features at pharmakb.com
Learn more